Search the Newsroom
Filter By
News Type
Showing 1 - 10 of 28 results
Children’s Hospital of Philadelphia, Penn Medicine Researchers Report High-Throughput Variant Re-Classification for Alagille Syndrome Disease Gene
Findings will help provide more accurate diagnoses to families.
Q&A with Binita M. Kamath, MBBChir, MRCP, MTR
CHOP’s new Chief of the Division of Gastroenterology, Hepatology and Nutrition shares her vision for the department’s future.
New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
The Latest in Liver Research: 2022
Active research at the Fred and Suzanne Biesecker Pediatric Liver Center.
Liver Disease in Children
Research in the lab and at the bedside offer new hope for young patients with biliary atresia, Alagille syndrome and other chronic liver disorders.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.